As of 2025-07-20, the Intrinsic Value of Repro Med Systems Inc (KRMD) is (5.65) USD. This KRMD valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 3.37 USD, the upside of Repro Med Systems Inc is -267.60%.
The range of the Intrinsic Value is (33.40) - (3.13) USD
Based on its market price of 3.37 USD and our intrinsic valuation, Repro Med Systems Inc (KRMD) is overvalued by 267.60%.
Note: result may not be accurate due to the invalid valuation result of DCF model.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (33.40) - (3.13) | (5.65) | -267.6% |
| DCF (Growth 10y) | (3.18) - (30.68) | (5.48) | -262.6% |
| DCF (EBITDA 5y) | (1.77) - (2.31) | (1,234.50) | -123450.0% |
| DCF (EBITDA 10y) | (1.93) - (2.55) | (1,234.50) | -123450.0% |
| Fair Value | -0.57 - -0.57 | -0.57 | -117.03% |
| P/E | (3.57) - (4.10) | (3.93) | -216.8% |
| EV/EBITDA | (1.49) - (1.85) | (1.71) | -150.9% |
| EPV | (1.91) - (2.81) | (2.36) | -170.1% |
| DDM - Stable | (1.67) - (23.96) | (12.82) | -480.4% |
| DDM - Multi | (1.73) - (19.58) | (3.20) | -195.0% |
| Market Cap (mil) | 155.49 |
| Beta | 1.09 |
| Outstanding shares (mil) | 46.14 |
| Enterprise Value (mil) | 147.18 |
| Market risk premium | 4.60% |
| Cost of Equity | 6.62% |
| Cost of Debt | 7.00% |
| WACC | 6.61% |